Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in Previously Treated Metastatic Colorectal Cancer
NCT06959550Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year and Objective Response Rate per iRECIST at 1 year. Started Jul 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06959550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959550.